Study summary

Mavacamten did not help people with nonobstructive HCM

ODYSSEY-HCM trial · 580 people, phase 3 · Published August 2025, New England Journal of Medicine

0.47ml/kg/min difference in peak oxygen uptake (not significant)

What was tested

Mavacamten against placebo for symptomatic nonobstructive hypertrophic cardiomyopathy, where the heart is thick but blood flow out is not blocked.

What they found

Peak oxygen uptake difference was 0.47 ml/kg/min (not significant).
Symptom scores improved 2.7 points more (not significant).
Drops in ejection fraction were more common with mavacamten.

What it means

Left nonobstructive HCM without an approved drug and set the stage for ACACIA-HCM.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.